Late breaking poster presentation with full 12-month follow-up results and 6-month crossover patient data for SENZA-PDN randomized controlled trial
Company to hold investor briefing on June 25, 2021 at 3:30 p.m. Pacific Time / 6:30 p.m. Eastern Time
REDWOOD CITY, California., June 22, 2021 / PRNewswire / – Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the management of chronic pain, announced today that data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Study (RCT) will enter the 81st scientific American Diabetes Association (ADA) meeting presented. 25-29 June, 2021. Nevro will also showcase the company’s HFX ™ platform for spinal cord stimulation (SCS) solutions at a virtual booth and host an investor briefing.
The Late Breaking Poster presentation describes the 12-month follow-up results and 6-month crossover patient data from the SENZA-PDN RCT. The aim of this study was to compare Nevro’s proprietary radio frequency SCS (10 kHz) plus conventional medical management (CMM) with CMM alone in 216 patients in 18 centers in the US. Previously published 6-month results showed significantly improved and sustained results with 10 kHz SCS and significant, sustained pain relief and improved health-related quality of life in patients with painful diabetic neuropathy.
“We are pleased that Dr. Petersen will for the first time share the significant 12-month results and especially the 6-month crossover patient data from our groundbreaking SENZA-PDN study at the ADA Scientific Sessions, “said D. Keith Grossmann, Chairman, CEO and President of Nevro. “No conventional, low-frequency SCS treatment has shown such positive results in treating PDN patients, and we believe that, once FDA approved, there is a significant opportunity to expand this innovative treatment option to PDN patients with the currently available agents cannot find relief from pharmacological options. “
The story goes on
Details of the presentation are given below:
Poster # 16-LB, Long-Term 10 kHz Spinal Cord Stimulation in Painful Diabetic Neuropathy: A Randomized Controlled Study
Presenting author: Dr. Erika Petersen
Appointment time: Friday June 25th 2021 at the 11:30 p.m. ET (Posters will be available for the duration of the meeting)
Note that only registered participants of the ADA Scientific Sessions have access to the poster presentation. If you are registered, the text of abstracts will be made available with an embargo on June 22, 2021. You can access the online planner for ADA Scientific Sessions 2021 from your desktop / laptop computer. You can also visit ADAMeetingNews.org for instructions on how to download the mobile app.
The company plans to publish these 12-month results, including the 6-month crossover patient data, in a peer-reviewed journal. The study participants will be observed for up to 24 months. Nevro also plans to sponsor a compendia and podcast series with the ADA on painful diabetic neuropathy due out later this year.
Nevro hosts analyst and investor briefing about June 25, 2021
Nevro is holding a briefing for analysts and investors on the topic Friday June 25th, starting at 3:30 p.m. PT / 6:30 p.m. ET. Nevro Chairman, CEO and President D. Keith Grossmann will host the event, which includes an update of clinical data for the Company’s SENZA-PDN and SENZA-NSRBP clinical trials and a question-and-answer session. Chief Medical Officer of Nevro, David Caraway, MD, PhD and Chief Financial Officer of Nevro, Rod MacLeod, will also attend the event.
Investors wishing to listen to the briefing can attend via conference call or webcast. The conference call can be accessed by calling (833) 968-2321 in the US or 7785602840 internationally by calling conference ID: 2819815. The live audio webcast can be accessed by clicking the Investor Events link at https: // nevro. com / English / us / investors / events-and-presentations / event-details / 2021 / Nevro-to-Host-Virtual-Investor-Briefing-from-ADA / default.aspx on 25th June. This event is not part of the official ADA Scientific Sessions.
About painful diabetic neuropathy (PDN)
The World Health Organization estimates 422 million adults with diabetes worldwide and a prevalence (8.5%) that has almost doubled in four decades.1 Diabetes can cause systemic damage with profound effects on health-related quality of life and is potentially life-threatening. Diabetic peripheral neuropathy is a common complication that manifests itself as pain and other dysesthesias, including numbness, burning, or tingling. Approximately 20% of patients with diabetes develop PDN, a progressive, potentially debilitating, chronic neuropathic pain disorder.2 In the US, it is estimated that approximately 140,000 to 200,000 PDN patients become refractory to conventional medical treatment each year, representing an overall addressable market opportunity of approx $ 3.5 billion to $ 5.0 billion.3.4
About the ADA Scientific Sessions – Virtual Experience
The American Diabetes Association’s scientific sessions provide an exclusive opportunity for researchers and health professionals from around the world to share ideas and learn about the latest advances in diabetes research, treatment, and care. Participants will have access to more than 3,000 original research presentations, participate in thought-provoking lectures with leading diabetes experts, and expand their professional network. For more information, see the ADA website: https://professional.diabetes.org/scientific-sessions
Publication of information on the Internet
Nevro regularly publishes information that may be important to investors in the Investor Relations section of its website at www.nevro.com. The company encourages investors and potential investors to regularly visit the Nevro website for important information about Nevro.
About Nevro
Headquarters in Redwood City, California, Nevro is a global medical technology company focused on delivering innovative products that improve the quality of life for patients with debilitating chronic pain. Nevro developed and commercialized Senza’s Spinal Cord Stimulation System (SCS), an evidence-based, non-pharmacological, neuromodulation platform for the management of chronic pain. Nevro’s proprietary 10 kHz therapy has shown in six peer-reviewed clinical studies to reduce or eliminate opioids in ≥ 65% of patients. The Senza® System, Senza II ™ System, and Senza® Omnia ™ System are the only SCS systems delivering Nevro’s proprietary 10 kHz therapy.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 Logo, HFX, the HFX Logo, HFX CONNECT, the HFX Connect Logo, HFX ACCESS, the HFX Access Logo, HFX COACH, the HFX Coach Logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp.
To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook, and Instagram.
1 World Health Organization. (2016). Global Report on Diabetes. World Health Organization. https://apps.who.int/iris/handle/10665/204871
2 Schmader KE. Epidemiology and quality of life effects of postherpetic neuralgia and painful diabetic neuropathy. Clin J. Pain. 2002; 18 (6): 350-354.
3 CDC National Diabetes Statistics Report 2020; Schmader KE. Epidemiology and quality of life effects of postherpetic neuralgia and painful diabetic neuropathy. Clin J. Pain. 2002; 18 (6): 350-354.
4 Trinity Partners Market Research 2017.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements that reflect the company’s current views and expectations of management under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: Our belief that there is a significant opportunity our innovative To extend SCS therapy as an option to PDN patients who cannot find relief with currently available pharmacological options; our plan to publish the results of the SENZA-PDN 12-month clinical trial, including 6-month crossover patient data, in a peer-reviewed journal; and our plan to sponsor a compendium and podcast series with the ADA on painful diabetic neuropathy. These forward-looking statements are based on information currently available to us or our current expectations, speak only as of the date and are subject to numerous risks and uncertainties, including our ability to successfully market our products; our ability to manufacture our products on demand; the amount and availability of third party reimbursement for our products; our ability to effectively manage our expected growth and the costs and expenses of operating our business; our ability to protect our intellectual property rights and proprietary technologies; our ability to conduct our business without violating the intellectual property rights and proprietary technologies of third parties; Competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These factors, along with those detailed in our Quarterly Report on Form 10-Q, filed on May 5, 2021, and any future filing with the Securities and Exchange Commission, could cause our actual results, performance or accomplishments to differ materially and adversely from those anticipated or implied in our forward-looking statements. We expressly disclaim any obligation, unless required by law, or undertake to update or revise such forward-looking statements.
Investors and media:
Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corporate Communications
650-433-3247 | julie.dewey@nevro.com
.
Cision
View original content to download multimedia: http://www.prnewswire.com/news-releases/nevro-announces-senza-pdn-clinical-data-presentation-at-the-american-diabetes-association-81st-scientific-sessions -301317016.html
SOURCE Nevro Corp.
